JP2022535120A5 - - Google Patents

Info

Publication number
JP2022535120A5
JP2022535120A5 JP2021572048A JP2021572048A JP2022535120A5 JP 2022535120 A5 JP2022535120 A5 JP 2022535120A5 JP 2021572048 A JP2021572048 A JP 2021572048A JP 2021572048 A JP2021572048 A JP 2021572048A JP 2022535120 A5 JP2022535120 A5 JP 2022535120A5
Authority
JP
Japan
Application number
JP2021572048A
Other languages
Japanese (ja)
Other versions
JP2022535120A (ja
JP7665534B2 (ja
JPWO2020247496A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035920 external-priority patent/WO2020247496A1/en
Publication of JP2022535120A publication Critical patent/JP2022535120A/ja
Publication of JPWO2020247496A5 publication Critical patent/JPWO2020247496A5/ja
Publication of JP2022535120A5 publication Critical patent/JP2022535120A5/ja
Application granted granted Critical
Publication of JP7665534B2 publication Critical patent/JP7665534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572048A 2019-06-04 2020-06-03 2,3,5-三置換ピラゾロ[1,5-a]ピリミジン化合物 Active JP7665534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857148P 2019-06-04 2019-06-04
US62/857,148 2019-06-04
PCT/US2020/035920 WO2020247496A1 (en) 2019-06-04 2020-06-03 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds

Publications (4)

Publication Number Publication Date
JP2022535120A JP2022535120A (ja) 2022-08-04
JPWO2020247496A5 JPWO2020247496A5 (https=) 2023-06-13
JP2022535120A5 true JP2022535120A5 (https=) 2023-06-13
JP7665534B2 JP7665534B2 (ja) 2025-04-21

Family

ID=73652950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572048A Active JP7665534B2 (ja) 2019-06-04 2020-06-03 2,3,5-三置換ピラゾロ[1,5-a]ピリミジン化合物

Country Status (11)

Country Link
US (1) US12410170B2 (https=)
EP (1) EP3980010A4 (https=)
JP (1) JP7665534B2 (https=)
KR (1) KR20220047247A (https=)
CN (1) CN114206332B (https=)
AR (1) AR119088A1 (https=)
AU (1) AU2020288610A1 (https=)
CA (1) CA3142712A1 (https=)
TW (1) TWI857071B (https=)
UY (1) UY38742A (https=)
WO (1) WO2020247496A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
WO2022226052A1 (en) * 2021-04-20 2022-10-27 The Regents Of The University Of Michigan Pi3k inhibitors, nanoformulations, and uses thereof
CN117295741A (zh) 2021-05-21 2023-12-26 艾库斯生物科学有限公司 Axl化合物
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ,インコーポレーテッド Axl阻害化合物
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
CN119072476A (zh) * 2022-03-02 2024-12-03 上海海雁医药科技有限公司 六元芳环并吡咯酮衍生物、其药物组合物及应用
CA3256561A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and their uses
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024046454A1 (zh) * 2022-09-01 2024-03-07 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
CN119768155A (zh) 2022-09-14 2025-04-04 艾库斯生物科学有限公司 依曲地南的分散体
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
EP4604920A1 (en) 2022-10-20 2025-08-27 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025146216A1 (zh) * 2024-01-05 2025-07-10 成都赜灵生物医药科技有限公司 六并五氮杂环酰胺类化合物及其用途
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
AU2007206860A1 (en) 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
GB0812309D0 (en) 2008-07-03 2008-08-13 Ucb Pharma Sa Therapeutic agents
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
AU2010341573B2 (en) 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
SG10201802061TA (en) 2013-09-25 2018-05-30 Vertex Pharma A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) * 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
US10786504B2 (en) 2014-09-03 2020-09-29 Rhizen Pharmaceuticals Sa Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
AR107840A1 (es) 2016-03-10 2018-06-13 Astrazeneca Ab INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US10961236B2 (en) 2016-09-22 2021-03-30 Astrazeneca Ab (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor
CN108017641B (zh) 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR20240152947A (ko) 2017-10-18 2024-10-22 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022535120A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)